JAKARTA - A leading vaccine manufacturer in China, Sinovac Biotech will conduct research to determine the impact of the Omicron variant on the inactivated COVID-19 vaccine.
"We will also evaluate whether it is necessary to develop a new vaccine to deal with the Omicron variant in the near future," Sinovac said in a statement in Beijing, China, quoted by Antara, Tuesday, November 30.
The Beijing-based vaccine manufacturer has been monitoring the development of cases of the Omicron variant.
"We are also actively collecting information and samples of Omicron variants through our worldwide network of partners," Sinovac said.
Previously, Sinovac had developed an inactivated COVID-19 vaccine for the Gamma and Delta variants.
"If needed, we will immediately develop and launch a new vaccine production on a large scale, in order to meet the needs of new vaccinations," said Sinovac.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
Most Popular Tags
#Prabowo Subianto #Pilkada Dki #online gambling #Mount Lewotobi male #pileupPopular
